<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 42 - THE PUBLIC HEALTH AND WELFARE</title></head><body>
<span style="font-weight:bold;font-size:12pt;">42 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 1994 Edition</span><br/>
<span style="font-size:10pt">Title 42 - THE PUBLIC HEALTH AND WELFARE</span><br/>
<span style="font-size:10pt">CHAPTER 6 - THE CHILDREN'S BUREAU</span><br/>
<span style="font-size:10pt">SUBCHAPTER II - GENERAL POWERS AND DUTIES</span><br/>
<span style="font-size:10pt">Part F - Licensing of Biological Products and Clinical Laboratories</span><br/>
<span style="font-size:10pt">subpart 1 - biological products</span><br/>
<span style="font-size:10pt">Sec. 262 - Regulation of biological products</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- documentid:42_262  usckey:420000000026200000000000000000000 currentthrough:19950104 documentPDFPage:255 -->
<!-- itempath:/420/CHAPTER 6/SUBCHAPTER II/Part F/subpart 1/Sec. 262 -->
<!-- itemsortkey:420AAJE -->
<!-- expcite:TITLE 42-THE PUBLIC HEALTH AND WELFARE!@!CHAPTER 6-THE CHILDREN'S BUREAU!@!SUBCHAPTER II-GENERAL POWERS AND DUTIES!@!Part F-Licensing of Biological Products and Clinical Laboratories!@!subpart 1-biological products!@!Sec. 262 -->
<!-- field-start:head -->
<h3 class="section-head">&sect;262. Regulation of biological products</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) Intrastate and interstate traffic; suspension or revocation of license as affecting prior sales</h4>
<p class="statutory-body">No person shall sell, barter, or exchange, or offer for sale, barter, or exchange in the District of Columbia, or send, carry, or bring for sale, barter, or exchange from any State or possession into any other State or possession or into any foreign country, or from any foreign country into any State or possession, any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, or arsphenamine or its derivatives (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of diseases or injuries of man, unless (1) such virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product has been propagated or manufactured and prepared at an establishment holding an unsuspended and unrevoked license, issued by the Secretary as hereinafter authorized, to propagate or manufacture, and prepare such virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product for sale in the District of Columbia, or for sending, bringing, or carrying from place to place aforesaid; and (2) each package of such virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product is plainly marked with the proper name of the article contained therein, the name, address, and license number of the manufacturer, and the date beyond which the contents cannot be expected beyond reasonable doubt to yield their specific results. The suspension or revocation of any license shall not prevent the sale, barter, or exchange of any virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product aforesaid which has been sold and delivered by the licensee prior to such suspension or revocation, unless the owner or custodian of such virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product aforesaid has been notified by the Secretary not to sell, barter, or exchange the same.</p>
<h4 class="subsection-head">(b) Falsely labeling or marking package or container; altering label or mark</h4>
<p class="statutory-body">No person shall falsely label or mark any package or container of any virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product aforesaid; nor alter any label or mark on any package or container of any virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product aforesaid so as to falsify such label or mark.</p>
<h4 class="subsection-head">(c) Inspection of establishment for propagation and preparation</h4>
<p class="statutory-body">Any officer, agent, or employee of the Department of Health and Human Services, authorized by the Secretary for the purpose, may during all reasonable hours enter and inspect any establishment for the propagation or manufacture and preparation of any virus, serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or other product aforesaid for sale, barter, or exchange in the District of Columbia, or to be sent, carried, or brought from any State or possession into any other State or possession or into any foreign country, or from any foreign country into any State or possession.</p>
<h4 class="subsection-head">(d) Regulations governing licenses; recall of product presenting imminent hazard; violations</h4>
<p class="statutory-body">(1) Licenses for the maintenance of establishments for the propagation or manufacture and preparation of products described in subsection (a) of this section may be issued only upon a showing that the establishment and the products for which a license is desired meet standards, designed to insure the continued safety, purity, and potency of such products, prescribed in regulations, and licenses for new products may be issued only upon a showing that they meet such standards. All such licenses shall be <!-- PDFPage:256 -->issued, suspended, and revoked as prescribed by regulations and all licenses issued for the maintenance of establishments for the propagation or manufacture and preparation, in any foreign country, of any such products for sale, barter, or exchange in any State or possession shall be issued upon condition that the licensees will permit the inspection of their establishments in accordance with subsection (c) of this section.</p>
<p class="statutory-body">(2)(A) Upon a determination that a batch, lot, or other quantity of a product licensed under this section presents an imminent or substantial hazard to the public health, the Secretary shall issue an order immediately ordering the recall of such batch, lot, or other quantity of such product. An order under this paragraph shall be issued in accordance with section 554 of title 5.</p>
<p class="statutory-body">(B) Any violation of subparagraph (A) shall subject the violator to a civil penalty of up to $100,000 per day of violation. The amount of a civil penalty under this subparagraph shall, effective December 1 of each year beginning 1 year after the effective date of this subparagraph, be increased by the percent change in the Consumer Price Index for the base quarter of such year over the Consumer Price Index for the base quarter of the preceding year, adjusted to the nearest 1/10 of 1 percent. For purposes of this subparagraph, the term &ldquo;base quarter&rdquo;, as used with respect to a year, means the calendar quarter ending on September 30 of such year and the price index for a base quarter is the arithmetical mean of such index for the 3 months comprising such quarter.</p>
<h4 class="subsection-head">(e) Interference with officers</h4>
<p class="statutory-body">No person shall interfere with any officer, agent, or employee of the Service in the performance of any duty imposed upon him by this section or by regulations made by authority thereof.</p>
<h4 class="subsection-head">(f) Penalties for offenses</h4>
<p class="statutory-body">Any person who shall violate, or aid or abet in violating, any of the provisions of this section shall be punished upon conviction by a fine not exceeding $500 or by imprisonment not exceeding one year, or by both such fine and imprisonment, in the discretion of the court.</p>
<h4 class="subsection-head">(g) Construction with other laws</h4>
<p class="statutory-body">Nothing contained in this chapter shall be construed as in any way affecting, modifying, repealing, or superseding the provisions of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.].</p>
<h4 class="subsection-head">(h) Exportation of partially processed biological products</h4>
<p class="statutory-body">(1)(A) A partially processed biological product which is not in a form applicable to the prevention, treatment, or cure of diseases or injuries of man, which is not intended for sale in the United States, and which is intended for further manufacture into final dosage form outside the United States in a country listed under section 802(b)(A)&nbsp;<sup><a href="#262_1_target" name="262_1">1</a></sup> of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 382(b)(4)(A)] may, upon approval of an application meeting the requirements of subparagraph (B), be exported to a country listed under section 802(b)(4) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 382(b)(4)]. The Secretary may not approve an application to export such a product unless the Secretary determines that the product is manufactured, processed, packaged, and held in conformity with current good manufacturing practice and the outside of the shipping package is labeled with the following statement: &ldquo;This product may be sold or offered for sale only in the following countries: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&rdquo;, the blank space being filled with a list of the countries to which export of the drug is authorized.</p>
<p class="statutory-body">(B) An application for the export of a partially processed biological product shall&mdash;</p>
<p class="statutory-body-1em">(i) describe the partially processed biological product to be exported,</p>
<p class="statutory-body-1em">(ii) list each country to which the product is to be exported,</p>
<p class="statutory-body-1em">(iii) contain a certification by the applicant that the product will not be exported to a country not listed under clause (ii),</p>
<p class="statutory-body-1em">(iv) identify the establishments in which the product is manufactured, and</p>
<p class="statutory-body-1em">(v) contain a certification by the applicant that the final product to be developed from the partially processed product is approved in the country to which it is to be exported or approval of the final product is being sought in such country.</p>
<br class="Q04" />
<p class="statutory-body">(2) A product described in paragraph (1) is not subject to licensure under this section.</p>
<p class="statutory-body">(3) If the Secretary determines that prohibiting the export of a product described in paragraph (1) is necessary for protection of the public health in the United States or the country to which it is to be exported, the Secretary may not approve an application under paragraph (1) for the export of such product.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(July 1, 1944, ch. 373, title III, &sect;351, 58 Stat. 702; 1953 Reorg. Plan No. 1, &sect;&sect;5, 8, eff. Apr. 11, 1953, 18 F.R. 2053, 67 Stat. 631; Sept. 2, 1958, Pub. L. 85&ndash;881, &sect;2, 72 Stat. 1704; Oct. 30, 1970, Pub. L. 91&ndash;515, title II, &sect;291, 84 Stat. 1308; Oct. 17, 1979, Pub. L. 96&ndash;88, title V, &sect;509(b), 93 Stat. 695; Nov. 14, 1986, Pub. L. 99&ndash;660, title I, &sect;105(a), title III, &sect;315, 100 Stat. 3751, 3783; June 16, 1992, Pub. L. 102&ndash;300, &sect;6(b)(1), 106 Stat. 240.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:referenceintext-note -->
<h4 class="note-head">References in Text</h4>
<p class="note-body">The effective date of this subparagraph, referred to in subsec. (d)(2)(B), is the effective date of section 315 of Pub. L. 99&ndash;660 which added subsec. (d)(2). See Effective Date of 1986 Amendment note set out below.</p>
<p class="note-body">The Federal Food, Drug, and Cosmetic Act, referred to in subsec. (g), is act June 25, 1938, ch. 675, 52 Stat. 1040, as amended, which is classified generally to chapter 9 (&sect;301 et seq.) of Title 21, Food and Drugs. For complete classification of this Act to the Code, see section 301 of Title 21 and Tables.</p>
<!-- field-end:referenceintext-note -->
<!-- field-start:amendment-note -->
<h4 class="note-head">Amendments</h4>
<p class="note-body">1992&mdash;Subsec. (c). Pub. L. 102&ndash;300, which directed substitution of &ldquo;Health and Human Services&rdquo; for &ldquo;Health, Education, and Welfare&rdquo;, could not be executed because the words &ldquo;Health, Education, and Welfare&rdquo; did not appear in original statutory text. Previously, references to Department and Secretary of Health and Human Services were substituted for references to Federal Security Agency and its Administrator pursuant to provisions cited in Transfer of Functions note below.</p>
<p class="note-body">1986&mdash;Subsec. (d). Pub. L. 99&ndash;660, &sect;315, designated existing provisions as par. (1) and added par. (2).</p>
<!-- PDFPage:257 --><p class="note-body">Subsec. (h). Pub. L. 99&ndash;660, &sect;105(a), added subsec. (h).</p>
<p class="note-body">1970&mdash;Subsecs. (a) to (c). Pub. L. 91&ndash;515 inserted &ldquo;vaccine, blood, blood component or derivative, allergenic product,&rdquo; after &ldquo;antitoxin&rdquo; wherever appearing.</p>
<p class="note-body">1958&mdash;Subsec. (d). Pub. L. 85&ndash;881 struck out &ldquo;made jointly by the Surgeon General, the Surgeon General of the Army, and the Surgeon General of the Navy, and approved by the Secretary&rdquo; after &ldquo;regulations&rdquo; in first sentence.</p>
<!-- field-end:amendment-note -->
<!-- field-start:effectivedate-amendment-note -->
<h4 class="note-head">Effective Date of 1986 Amendment</h4>
<p class="note-body">Section 105(b) of Pub. L. 99&ndash;660 provided that: &ldquo;Paragraph (1) of section 351(h) of the Public Health Service Act [subsec. (h)(1) of this section] as added by subsection (a) shall take effect upon the expiration of 90 days after the date of the enactment of this Act [Nov. 14, 1986].&rdquo;</p>
<p class="note-body">Amendment by section 315 of Pub. L. 99&ndash;660 effective Dec. 22, 1987, see section 323 of Pub. L. 99&ndash;660, as amended, set out as an Effective Date note under section 300aa&ndash;1 of this title.</p>
<!-- field-end:effectivedate-amendment-note -->
<!-- field-start:function-transfer-note -->
<h4 class="note-head">Transfer of Functions</h4>
<p class="note-body">Functions of Public Health Service, Surgeon General of Public Health Service, and all other officers and employees of Public Health Service, and functions of all agencies of or in Public Health Service transferred to Secretary of Health, Education, and Welfare by Reorg. Plan No. 3 of 1966, eff. June 25, 1966, 31 F.R. 8855, 80 Stat. 1610, set out as a note under section 202 of this title. Secretary of Health, Education, and Welfare redesignated Secretary of Health and Human Services by section 509(b) of Pub. L. 96&ndash;88 which is classified to section 3508(b) of Title 20, Education.</p>
<p class="note-body">References to Secretary and Department of Health, Education, and Welfare substituted for references to Federal Security Administrator and Federal Security Agency, respectively, pursuant to Reorg. Plan No. 1 of 1953, &sect;5, set out as a note under section 3501 of this title, which transferred all functions of Federal Security Administrator to Secretary of Health, Education, and Welfare and all agencies of Federal Security Agency to Department of Health, Education, and Welfare. Federal Security Agency and office of Administrator abolished by section 8 of Reorg. Plan No. 1 of 1953. Secretary and Department of Health, Education, and Welfare redesignated Secretary and Department of Health and Human Services by section 509(b) of Pub. L. 96&ndash;88 which is classified to section 3508(b) of Title 20.</p>
<!-- field-end:function-transfer-note -->
<!-- field-start:crossreference-note -->
<h4 class="note-head">Cross References</h4>
<p class="note-body">Regulation of biological products for use in treatment of domestic animals, see sections 151 to 159 of Title 21, Food and Drugs.</p>
<!-- field-end:crossreference-note -->
<!-- field-end:notes -->
<!-- field-start:secref -->
<h4 class="note-head">Section Referred to in Other Sections</h4>
<!-- field-end:secref -->
<!-- field-start:sectionreferredto -->
<p class="note-body">This section is referred to in sections 236, 263, 300aa&ndash;22, 300aa&ndash;23, 1396r&ndash;8 of this title; title 21 sections 321, 353, 360aa, 360bb, 360cc, 360ee, 379g, 382, 392; title 26 section 28; title 35 section 156.</p>
<!-- field-end:sectionreferredto -->
<!-- field-start:footnote -->
<p class="footnote"><a href="#262_1" name="262_1_target"><sup>1</sup>&nbsp;So in original. Probably should be section &ldquo;802(b)(4)(A)&rdquo;.</a></p>
<!-- field-end:footnote -->


</body></html>